Global Varicella Zoster Infection Treatment Industry is expected to reach a valuation of US$2.0 Billion by 2028, with a compound annual growth rate of 4.1% | FMI

Global Varicella Zoster Infection Treatment Industry
Global Varicella Zoster Infection Treatment Industry

The Global Varicella Zoster Infection Treatment Industry is poised for significant growth, according to a new report from Future Market Insights (FMI). Titled “Global Varicella Zoster Infection Treatment Industry,” the study reveals the industry exceeding US$ 1.5 billion in 2020 and projects a steady Compound Annual Growth Rate (CAGR) of 4.1% through 2028. This upward trend is expected to propel the market towards a remarkable valuation of US$ 2.0 billion by 2028.

The surge in growth witnessed in the Varicella Zoster Treatment Industry can be attributed to several key factors. Advances in medical research, coupled with technological innovations, have played a pivotal role in shaping the industry’s upward trajectory. Additionally, there is a growing global awareness of varicella-zoster infection, further fueling the demand for effective treatments.

Acyclovir Leads the Way: In 2022, acyclovir is set to dominate the global varicella zoster infection treatment market, accounting for more than 55.7% of the market share, according to the latest data from Future Market Insights.

Understanding Varicella: Varicella, commonly known as chickenpox, can lead to complications such as secondary bacterial skin infections, cerebellitis, encephalitis, hemorrhagic complications, and viral and bacterial pneumonia when it manifests acutely. The epidemiology of varicella is influenced by climate, with 90% of people in temperate climatic regions becoming infected before adolescence. In tropical climates, Varicella Zoster Virus (VZV) infection occurs later in life, and adults are more susceptible to it than children.

The Challenge of Herpes Zoster: Herpes zoster, or shingles, is a sporadic disease caused by the reactivation of latent VZV in the sensory nerve ganglia. It is characterized by severe pain with a dermatomal distribution and, at times, followed by post-herpetic neuralgia, which can be chronic and debilitating among the geriatric population.

As the Varicella Zoster Infection Treatment Industry continues to evolve, these insights provide valuable information for stakeholders, healthcare professionals, and researchers. The market’s upward trajectory highlights the importance of continued research and development in this critical healthcare segment.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-6466

Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.

To cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships to make use of the technology of the other leading companies and are also focussing on research and development.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and fetal risks of varicella-zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.

These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment industry.

Grab Your Discount Now Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-6466

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs for the Global Varicella Zoster Infection Treatment Industry. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Global Varicella Zoster Infection Treatment Industry Key Players:

  • Novartis AG,
  • Pfizer Inc.,
  • Abbott Laboratories,
  • Sun Pharmaceuticals Industries Ltd.,
  • Valeant Pharmaceuticals International Inc.,
  • Teva Pharmaceutical Industries Ltd.,
  • Dr. Reddy’s Laboratories, ltd.,
  • Mylan N.V.  and
  • GlaxoSmithKline

Global Varicella Zoster Infection Treatment Industry Segmentation – by Category

By Drug Type:

  • Acyclovir
  • Valacyclovir
  • Famciclovir

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-6466

By Route of Administration:

  • Oral
  • Injectable
  • Topical

By Distribution Channel:

  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Ronak Shah

Associate Vice President at Future Market Insights is deeply committed to uncovering actionable insights for consumer and food and beverage players. She brings a unique blend of analysis, industry trends, and consumer behavior to put data into perspective.

What she makes out of data becomes a delight to read. She has authored many opinions, including for publications like Process Industry Informer and Spinal Surgery News, as she understands the market pulse and consumers' shifting preferences.

She likes to bring experts to a roundtable to weigh the impact of a trend on an industry. Catch up with her discussion on the impact of AI in packaging.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these